Sign in
IMRN Stock Price, Chart, Stats & News
Immuron Limited
Save
6.83M
Market cap
–
Current P/E
–
Forward P/E
IMRN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 64.60% |
Operating margin | -69.39% |
Pretax margin | -68.40% |
Net margin | -65.18% |
Effective tax rate | 4.70% |
ROA | -56.21% |
ROE | -86.07% |
D/E | – |
Interest coverage ratio | -1400.22x |
IMRN valuation
P/E | – |
P/S | 0.58x |
P/B | 0.61x |
P/CF | -0.83x |
P/FCF | -0.78x |
P/OCF | -0.83x |
PEG | -0.01x |
EV multiple | -1.93x |
About
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products.
Similar securities
Based on sector and market capitalization
Report issue